Muscle-Derived Extracellular Vesicle Isolation for Tissue-Specific Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods fail to isolate extracellular vesicles (EVs) from bodily fluids that are specific to a particular tissue, making it difficult to determine their origin and target delivery, limiting their use as biomarkers or therapeutic agents.

Innovation Solution

Developed methods for isolating muscle-derived EVs using capture agents that bind specifically to molecules on their surface, allowing for the isolation of EVs from bodily fluids and cell culture media.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If EVs are isolated from bodily fluids using conventional methods, then EVs can be obtained for analysis, but it is impossible to determine their tissue origin or target delivery

Engineering Contradiction:

Improvetissue origin determinationVSAvoidtissue specificity information

Core Design Contradiction:

Measurement precisionVSLoss of information

Solution Approach 1:

The patent uses tissue-specific markers as intermediary substances that bridge the gap between EVs and their tissue of origin. These markers (proteins, lipids, or nucleic acids) are naturally associated with specific tissues and serve as identifiers, allowing researchers to trace EVs back to their source tissue without direct observation of the tissue itself.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces physical isolation methods (centrifugation, filtration) with molecular recognition methods. Instead of mechanically separating EVs based on size or density, the invention uses specific molecular interactions between capture agents and tissue-specific markers on EV surfaces to isolate and identify EVs from particular tissues.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Adaptability or versatility

If EVs from multiple tissues are present in bodily fluids, then EVs are available for therapeutic delivery, but the target tissue cannot be identified

Engineering Contradiction:

Improvetherapeutic delivery capabilityVSAvoidtarget tissue information

Core Design Contradiction:

Adaptability or versatilityVSLoss of information

Solution Approach 1:

The patent employs capture agents as intermediary molecules that specifically recognize and bind to tissue-specific markers on EVs. These capture agents (antibodies, aptamers, or other binding molecules) serve as mediators between the mixed population of EVs and the researcher, enabling selective isolation of EVs from the desired tissue source while maintaining their therapeutic cargo.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent applies the principle of local quality by endowing specific subsets of EVs with unique identifying characteristics (tissue-specific markers) while they circulate in the mixed bodily fluid environment. This allows each EV population to be distinguished and isolated based on its local molecular signature, even though all EVs share common structural features.

Inventive Principle:

Principle #3Local quality

3Productivity

If conventional EV isolation methods are used, then EVs can be recovered, but tissue-specific characterization is not possible

Engineering Contradiction:

ImproveEV isolation efficiencyVSAvoidtissue-specific characterization

Core Design Contradiction:

ProductivityVSMeasurement precision

Solution Approach 1:

The patent introduces capture agents as intermediary substances that enable simultaneous achievement of high isolation efficiency and tissue-specific characterization. These agents bind specifically to tissue-marked EVs, allowing selective capture and enrichment of EVs from particular tissues while maintaining high recovery rates through efficient binding interactions.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the isolation parameter from physical properties (size, density) to molecular recognition properties (specific antigen-antibody or ligand-receptor binding). This parameter change enables both efficient isolation (through high-affinity binding) and tissue-specific identification (through marker-specific recognition) to occur simultaneously.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables the detection and monitoring of neuromuscular disorders by characterizing components of isolated EVs, delivering therapeutic agents, and assessing treatment effectiveness.

Implementation Method 1

contacting the bodily fluid with a capture agent that specifically binds to a molecule on the surface of muscle-derived extracellular vesicles to form a capture agent: extracellular vesicle complex

Methodology Applied

Scientific EffectSpecific binding: Adsorption

Data Source

PatentUS20260049272A1Extracellular vesicles as biomarkers and therapeutics for neuromuscular disorders

Publication Date: 2026.02.19 IOWA STATE UNIV RES FOUND INC

AI summary

This invention relates to extracellular vesicles and method of isolated tissue-specific extracellular vesicles from bodily fluids. The invention further relates to methods of using extracellular vesicles for diagnostic applications for detecting and monitoring diseases, conditions, and damage in a subject. The invention also relates to methods of using extracellular vesicles for therapeutic applications for treating diseases, conditions, and damage in a subject.